The successful cloning and expression of active human rhinovirus 3C protease in E. coli enables in vitro assays for studying its biological activity.
Answers are grounded in this paper and cite their sources.
Enables in vitro rhinovirus 3C protease assays; leaves open clinical translation in cardiovascular research.
A cDNA encoding the viral protease from the 3C region of human rhinovirus type 14 was expressed in Escherichia coli through the use of a periplasmic secretion vector. The recombinant protease contained an eight amino acid N-terminal extension that enabled its detection by a specific antibody. It was expressed at a level of approximately 1 mg/L of E. coli culture. Biological activity of the protease was assessed in vitro by using a chemically synthesized peptide consisting of a consensus picornavirus protease cleavage site, Arg-Ala-Glu-Leu-Gln-Gly-Pro-Tyr-Asp-Glu. The peptide was cleaved by the recombinant protease at the Gln-Gly bond, generating the product peptides Arg-Ala-Glu-Leu-Gln and Gly-Pro-Tyr-Asp-Glu, which could be separated from the substrate peptide by reversed-phase HPLC. An in vitro assay for the rhinovirus 3C protease was developed by observing the rate of disappearance of the substrate peak from chromatograms of the supernatants of digestion mixtures.
No takes yet. Share an insight, caveat, or question.
Libby et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: